Understanding the Role of the Human Metagenome in Obesity, Metabolic Diseases, Chronic Inflammation, Sarcopenia and Sarcopenic Obesity - a Pilot Study

What this Trial Is About

Researchers are investigating the role of the human metagenome and associated metabolites in health and disease, focusing on obesity, sarcopenia, chronic inflammation, and metabolic syndrome. This observational cohort study aims to uncover differences in the metagenome and metabolome that may influence these chronic inflammatory conditions and metabolic disorders, potentially guiding personalized medicine approaches in the future. Participants are grouped into obese individuals (BMI greater than 27.5 kg/m2), sarcopenic patients defined by specific muscle strength, gait speed, and muscle mass criteria, and healthy controls without obesity or sarcopenia. Samples including fecal, salivary, urine, serum, and mucosal specimens will be collected for metagenomic sequencing and metabolomic testing. Participants will continue their routine clinical treatments as usual, with no specific study interventions applied. During the study, researchers will collect and analyze biological samples to track changes in the metagenome and metabolome over one year. This includes repeat assessments to observe alterations related to disease states or ongoing treatments. The study involves adults aged 21 to 99 years and includes healthy volunteers. The main outcomes measured are metagenomic and metabolomic changes over a 1-year period, helping to enhance understanding of metabolic diseases and aging-related conditions.

Pilot Study of the Human Metagenome in Metabolic Diseases